Archive for the 'Keytruda' Category

Keytruda news feed.

Less than Half of Cancer Patients Eligible for Immunotherapy Treatments

In late 2017, the FDA approved Keytruda (pembrolizumab) as an immunotherapy treatment for cancer.  It’s typically used to treat inoperable metastatic non-small cell lung cancer and melanoma but it has also been approved by the FDA to treat any unresectable or metastatic solid tumor, such as those found in mesothelioma. Immunotherapy is a type of

more

New Clinical Trial Underway for Immunotherapy Treatment; CA-170

A new immunotherapy treatment that has recently been administered to a patient suffering from mesothelioma has researchers and scientists optimistic that if results are positive, this treatment could be more effective than Keytruda, the immunotherapy treatment that has had major success in non-small cell lung cancer  The name of the treatment is CA-170, and while

more

Immunotherapy – What Side Effects Can You Expect?

As the success of immunotherapy treatments in improving survival and symptom management for cancer patients have started to become known, those suffering from cancer such as mesothelioma and lung cancer may now be given options in terms of the best course of treatment. Immunotherapy works with the body’s own natural defense system by strengthening and

more

Immunotherapy May Help Extend the Lives of Lung Cancer and Mesothelioma Patients

Immunotherapy is revolutionizing the health care industry by adding extra years of life to people with lung cancer. A few years ago it was rare for patients with an advanced stage of this disease to live past two years but today it has become more common to do so. Immunotherapy treatment works by boosting immune

more

Biomarker CD47 as a Successful Diagnostic and Treatment Tool

Survival rates for diffuse mesothelioma are notoriously low with the median survival ranging between 12 to 22 months.  A contributing factor to treatment being ineffective is that the disease if often in the advanced stages by the time it is noticed and diagnosed. Early detection may be a key factor in fighting this illness effectively,

more

ONCOS-102 Passes Safety Evaluation in Phase I Clinical Trials, Phase II Clinical Trial Recommended

A new immunotherapy developed by Targovax has recently passed Phase I clinical trials and is set to begin Phase II evaluation of this new treatment that may help those suffering from mesothelioma. ONCOS-102 was used in separate Phase I clinical trials; one in combination with chemotherapy, and one with immunotherapy. Cisplatin and pemetrexed are two

more

Last update: April 01, 2019. 03:30:08 pm.